There is a unwavering determination in Nicolas Wolikow and Simon Istolainen that we had never encountered before, the kind you find in elite athletes, leaving no room for failure. And for good reason: eradicating cancer is a mission that allows no hesitation. Cure51 is a French TechBio company dedicated to discovering new cancer treatments, with three defining characteristics.
First, the radical mindset we observed in the founders runs through the entire way they work. It responds to a need for extreme efficiency. Second, while research usually focuses on the biology of the 97% of patients who die from the deadliest cancers, Cure51 focuses on the 3% who survive: the Outliers. They are the first to use life to treat death. This singular approach places the company on a fundamentally different path. Finally, Cure51 is built as a collective effort. Beyond patients and survivors, the project brings together, in an unprecedented way, both the private and public sectors: experts in computing, medicine and biology, more than 50 leading oncology centres, doctors and hospitals, across the world. Following life means taking a step back and accepting a simple truth: the company is not the centre.
The identity we created for Cure51 could therefore only be radical, distinctive and alive.
The symbol is inspired by a scientific survival curve used in the company’s research. It represents both the journey of scientific discovery and human resilience, with a single dot marking the cancer survivor. The typeface, JetBrains Mono, originally designed for coding and data environments, reflects the brand’s scientific precision and analytical mindset. We chose not to define a colour palette, giving teams the freedom to use any colour across the spectrum. The multitude of circles, each representing a patient, forms a visual language. The photography is human, raw and highly realistic. It does not embellish but shows life as it is. A new strategic, visual and verbal identity, along with a new website, now supports Cure51 in their fight against cancer.